MAPT and Alzheimer disease: The loading of nicotinamide, an HDAC inhibitor into the SL NPs, can significantly reduce cognitive impairment associated with AD by reducing the phosphorylation of Tau proteins in rat model (Vakilinezhad et al., 2018).